Mia Hindi, MD
Gastroenterology · Newburgh, INNPI 1750582037
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 442 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 45.7% of the total. Reporting peaked in 2022 at $1,000 and has fallen 50.3% since, to $497 in 2025.
Across 442 payments — averaging $11.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$1K
- Bristol Myers Squibb$938
- Pfizer$80
- Takeda Pharmaceuticals U.S.A., Inc.$63
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$49
- plus $230 from 9 others
Across 7 payments — averaging $3167.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$22K
What the payments were for
- Food & beverage$4,85697%
- Education$1563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 243 | $2,289 |
| Johnson & Johnson | 109 | $1,364 |
| Bristol Myers Squibb | 67 | $938 |
| Pfizer | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Ferring Pharmaceuticals Inc. | 3 | $46 |
| Merck | 1 | $43 |
| Sanofi | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Bayer | 1 | $23 |
| Medtronic | 1 | $18 |
| Gilead | 1 | $14 |
| Amgen | 1 | $13 |
| Pinnacle Biologics, Inc | 1 | $13 |
How this compares
$5,012 in reported general payments places this provider in the 65th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 36 | $396,956 |
| Mesalamine | 67 | $19,491 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 91 | $15,623 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 75 | $12,122 |
| LinzessLinaclotide | 22 | $11,976 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 138 | $9,116 |
| Mesalamine ErMesalamine | 26 | $5,371 |
| Omeprazole | 452 | $4,810 |
| Dicyclomine Hcl | 29 | $939 |
| Pantoprazole Sodium | 101 | $841 |
| LoperamideLoperamide Hcl | 33 | $745 |
| Famotidine | 52 | $371 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $297 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 20 | $162 |
| Promethazine Hcl | 13 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $46 | $15,62391 claims |
| AbbVieLinzess | $2,289 | $11,97622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in Newburgh
- Aaron PughNewburgh$22K
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Jonathan ObertNew Albany$302K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Matthew BohmWestfield$239K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
- David PoundIndianapolis$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.